Anti-HLA monoclonal chimeric immunoglobulin, method and kit implementing such a monoclonal chimeric immunoglobulin

1. A process for producing a calibration curve, the process comprising:

preparing a plurality of solutions (S n ) of a monoclonal chimeric immunoglobulin, each solution (S n ) having a defined concentration value (C n ) of said monoclonal chimeric immunoglobulin, and then

placing each solution (S n ) in contact with the same defined quantity of at least one immobilized HLA class II antigen, and

producing the calibration curve, in which each defined concentration value (C n ) is associated with a measured value (V n ) of a parameter, said measured value (V n ) representing a quantity (Q n ) of the monoclonal chimeric immunoglobulin linked to the defined quantity of each immobilized HLA class II antigen,

forming from pairs (C n , V n ) of defined concentration (C n ) and measured value (V n ), the calibration curve showing the variation of the measured value (V n ) as a function of the defined concentration (C n ) of monoclonal chimeric immunoglobulin of each solution (S n ) of monoclonal chimeric immunoglobulin,

wherein the monoclonal chimeric immunoglobulin consists of:

two polypeptide heavy chains (H) of molecular weight from 40 kDa to 60 kDa, and

two polypeptide light chains (L) of molecular weight from 20 kDa to 30 kDa, wherein:

each heavy chain (H) comprises:

a heavy chain variable region (V H ) of a monoclonal antibody selected from the group consisting of monoclonal antibodies specific to monomorphic epitopes of HLA class II, and

a heavy chain constant region (C H ) of a human immunoglobulin selected from the group consisting of IgAs, IgGs and IgMs,

and wherein:

each light chain (L) comprises:

a light chain variable region (V L ) of a monoclonal antibody selected from the group consisting of monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens, and

a light chain constant region (CO of a human immunoglobulin that is a kappa chain

and wherein the two polypeptide heavy chains (H) are identical and the two polypeptide light chains (L) are identical, where

light chains (L) are of sequence SEQ ID NO: 5, and

heavy chains (H) are identical and selected from the group consisting of sequence SEQ ID NO: 6, sequence SEQ ID NO: 7 and sequence SEQ ID NO: 8.

2. The process of claim 1 , wherein the parameter is selected from the group consisting of a fluorescence parameter, a luminescence parameter, and a colorimetry parameter.

3. The process of claim 2 , wherein the fluorescence parameter is fluorescence intensity.

4. The process of claim 1 , wherein:

a) each immobilized HLA class II antigen is an HLA class II antigen immobilized on the surface of particles,

b) the immobilized HLA class II antigens and each solution of monoclonal chimeric immunoglobulin directed against the HLA class II antigens of the particles are brought into contact under conditions suitable for stable binding between the HLA class II antigens of the particles and the monoclonal chimeric immunoglobulin of each solution of monoclonal chimeric immunoglobulin, and then

c) the monoclonal chimeric immunoglobulins that are not bound to the HLA class II antigens of the particles of the solid substrate are removed by washing, and then

d) the monoclonal chimeric immunoglobulins that are bound to the HLA class II antigens of the particles are brought into contact with a solution of a secondary antibody which is selected from the group consisting of fluorescent secondary antibodies, luminescent secondary antibodies and photoabsorbent secondary antibodies and which is directed against the monoclonal chimeric immunoglobulin, under conditions suitable for stable binding between the monoclonal chimeric immunoglobulin and the secondary antibody, and then

e) the secondary antibody that is not bound to the monoclonal chimeric immunoglobulin is removed by washing, and then

f) at least one parameter of the secondary antibody that is bound to each particle is measured, and there is assigned to that measurement a measured value (V n ) of said parameter selected from the group consisting of a fluorescence parameter, a luminescence parameter and a colorimetry parameter, and then

g) the calibration curve is formed, and then

h) there is derived from the calibration curve a fluorescence intensity threshold value indicating the presence of the anti-HLA antibody in each solution (S n ).

5. The process of claim 1 , wherein each immobilized HLA class II antigen is an HLA class II antigen presented at the surface of at least one cell.

6. The process of claim 1 , in a method for the screening or quantification of anti-HLA antibodies chosen from the group consisting of multiplex quantitative immunofluorimetry methods, flow cytometry methods, methods of immunoenzymatic assay on a solid substrate, and complement-dependent microlymphocytotoxicity methods.

7. The process of claim 1 , comprising a step of calculating a threshold value of the parameter beyond which the concentration of monoclonal chimeric immunoglobulin is significantly greater than 0.